AbbVie, Galapagos aim to beat Vertex in CF

 
• By Eleanor Malone
  
Generate a summary of this article
Listen to this article
Beta

AbbVie has signed a $405m deal with Galapagos of Belgium which will see the two companies pool resources with the aim of developing a superior treatment for cystic fibrosis to Vertex Pharmaceuticals' Kalydeco (ivacaftor). More than a hundred staff from the two partners will work together to advance Galapagos's early-stage in-house research and develop CF transmembrane conductance regulator (CFTR) therapies.

AbbVie has signed a $405m deal with Galapagos of Belgium which will see the two companies pool resources with the aim of developing a superior treatment for cystic fibrosis to Vertex Pharmaceuticals' Kalydeco (ivacaftor). More than a hundred staff from the two partners will work together to advance Galapagos's early-stage in-house research and develop CF transmembrane conductance regulator (CFTR) therapies.

AbbVie has agreed to pay $45m up front and up to $360m in milestones to its partner, with which it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Dermatological

Galderma Gets First Biologic To Market With Nemluvio Approval

 
• By Jessica Merrill

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis. 

Dupixent Data Could Scratch A Regulatory Itch

 
• By Elizabeth Cairns

New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.

Leo Shrugs Off Timber Drug Failure As Revenues Roar

 
• By Kevin Grogan

The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.

Leo’s Congenital Ichthyosis Candidate Fails Phase III Study

 
• By Joseph Haas

TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.